NFX Nuformix Plc

TIDMNFX

RNS Number : 3019R

Nuformix PLC

28 October 2019

28 October 2019

Nuformix plc

("Nuformix" or "the Company"),

Issue of Equity

Following the receipt of Notice of Conversion of Loan Note, 8,716,512 ordinary shares of 0.1p each in the Company (the "Loan Note Shares") have been issued to the Loan Note holder following exercise at the agreed price of 2.75p per share.

Application has been made to admit the Loan Note Shares to trading on the London Stock Exchange on 24 October 2019, and dealings in the Loan Note Shares are expected to commence on 29 October 2019.

The Company's announcement on this matter on 24 May 2019 refers to the issue of equity referred to above.

The Company further announces that following the receipt of Notice of Exercise, 250,000 ordinary shares of 0.1p each in the Company (the "Warrant Shares") have now been issued to the Warrants holder following exercise at the agreed price of 4p per share.

Application has been made to admit the Warrant Shares to trading on the London Stock Exchange on 24 October 2019, and dealings in the Warrant Shares are expected to commence on 29 October 2019.

Following the issue of the Loan Note Shares and Warrant Shares the total number of shares now in issue is 469,716,512 ordinary shares with voting rights attached (one vote per share). There are no shares held in treasury.

This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Nuformix plc under the Disclosure and Transparency Rules.

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

Enquiries:

 
 Nuformix plc 
  Dr Dan Gooding, Chief Executive 
  Officer                            +44 (0)1223 62722 
 Email: info@nuformix.com 
 

About Nuformix plc www.nuformix.com

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix's IP portfolio of granted patents covers cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEGMMZGRRFGLZG

(END) Dow Jones Newswires

October 28, 2019 04:30 ET (08:30 GMT)

Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024